A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 20 September 2023
platelet count
renal function
bone marrow procedure
colony stimulating factor
neutrophil count
high-risk neuroblastoma
mycn protein
Accepts healthy volunteers


The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.

Condition Neuroblastoma
Treatment GM-CSF, β-glucan, OPT-821, OPT-821
Clinical Study IdentifierNCT04936529
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on20 September 2023

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note